reviewed april 2026|next review october 2026|88 physicians psi has verified|3178 published studies
Thymulin (FTS/ZnFTS)
Thymulin (FTS, ZnFTS) is a zinc-dependent nonapeptide produced exclusively by thymic epithelial cells, the only thymic hormone whose biological activity absolutely requires a zinc metal cofactor, creating a direct molecular link between zinc nutritional status and immune function.
Evidence landscape: 3178 published studies
3,178 published items. 22 human studies and 153 animal studies.
- 22 Human
- 153 Animal
- 25 Reviews
- 2978 Other research
Not FDA-approved. Not in clinical development. Thymulin is a naturally occurring (the body's own) thymic hormone characterized in the 1970s. No therapeutic product exists.
Not available as a therapeutic. Research-grade thymulin is available for laboratory use. Not sold as a supplement or medication.
Thymulin is the only thymic hormone that absolutely requires zinc for biological activity. It is a nonapeptide (9 amino acids) produced exclusively by thymic epithelial cells. Part of a family of thymic factors that includes thymosin alpha-1, thymopoietin, and thymalin.
PSI Assessment
Among the hormones produced by the thymus gland, thymulin occupies a unique position: it is the only one that cannot function without zinc. This creates a direct molecular link between nutritional zinc status and immune competence. As the thymus shrinks with age (a process called thymic involution), thymulin levels decline. Zinc deficiency further reduces thymulin activity, adding to age-related immune decline. Bach and Dardenne at Necker Hospital in Paris identified and characterized this connection in the 1970s, establishing one of the clearest mechanistic links between a micronutrient and immune function. The research base includes 3,178 published items, with 22 human studies and 153 animal studies. No controlled human trials of thymulin supplementation have been completed.
The only thymic hormone requiring zinc for activity. A direct molecular link between zinc nutrition and immune function. Levels decline with both aging and zinc deficiency.
The mechanism links zinc biology to immune function through a single peptide. Thymulin must bind Zn2+ to become biologically active. Once zinc-bound, it promotes T-cell differentiation and maturation by acting on bone marrow-derived T-cell precursors. Thymulin levels decline with thymic involution during aging, and zinc deficiency further reduces activity, providing a mechanistic explanation for age-related and nutrition-related immune decline. Bach and Dardenne at Necker Hospital in Paris identified and characterized thymulin in the 1970s.
What the evidence supports
Thymulin requires zinc for biological activity, establishing a direct molecular link between zinc nutritional status and immune function. T-cell maturation effects are documented across animal models. Circulating thymulin levels decline with both thymic involution and zinc deficiency. The zinc-thymulin-immunity axis is independently confirmed by multiple research groups.
What is not yet established
Whether thymulin supplementation reverses age-related immune decline in controlled human trials. Optimal dosing and delivery. Whether zinc supplementation alone restores thymulin activity sufficiently without exogenous thymulin. Long-term effects of thymulin administration.
Research Evidence
The findings below cover thymulin's zinc-dependent mechanism, its role in T-cell maturation, and the connection to aging and nutritional status.
Evidence by condition
Evidence dimensions available for each condition Thymulin (FTS/ZnFTS) has been studied for.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Immunosenescence | ||||
| Zinc-Immune Connection | ||||
| T-Cell Maturation | ||||
| Thymic Function |
Thymulin requires zinc binding for biological activity. The zinc-thymulin complex (ZnFTS) is the only biologically active form, and zinc deficiency directly reduces circulating active thymulin levels.
This zinc requirement creates a unique mechanistic link between nutritional status and thymic immune function. Multiple independent research groups have confirmed this finding.
22 Human|153 Animal|25 Reviews
View all 3178 indexed studiesHow Thymulin (FTS/ZnFTS) Works
Thymulin is a naturally occurring (the body's own) zinc-dependent nonapeptide produced exclusively by thymic epithelial cells. It promotes T-cell differentiation by binding to receptors on bone marrow-derived T-cell precursors. Zinc binding is absolutely required for receptor recognition and biological activity.
Thymus trains immune cells using thymulin.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Zinc metallopeptide promoting T cell differentiation.
What is Thymulin (FTS/ZnFTS) being studied for?
Researchers are studying Thymulin (FTS/ZnFTS) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Thymulin (FTS/ZnFTS) overall. This means a compound can have human studies for one condition but only animal data for another.
Immunosenescence
·Animal StudiesThymulin levels decline with thymic involution during aging. This decline parallels the broader deterioration of T-cell immunity observed in older populations. The zinc-thymulin axis provides one mechanistic explanation for age-related immune decline.
Limitations: No controlled human trials of thymulin supplementation for age-related immune decline have been completed. Whether restoring thymulin levels reverses immunosenescence remains undemonstrated.
Zinc-Immune Connection
·Animal StudiesThe absolute zinc requirement for thymulin activity provides a clear molecular explanation for zinc deficiency-related immune impairment. Zinc supplementation in deficient individuals has been shown to restore thymulin activity.
Limitations: Whether the thymulin pathway is the primary mechanism linking zinc to immunity, or one of several parallel pathways, is not fully resolved.
T-Cell Maturation
·Animal StudiesThymulin promotes differentiation of T-cell precursors into mature T-cells by binding to high-affinity receptors. This function is well-characterized in animal models and cell culture.
Limitations: Human studies of exogenous thymulin administration for T-cell maturation have not been conducted.
Thymic Function
·PreclinicalGene therapy approaches using thymulin have shown immune restoration in aged animal models. Thymulin gene expression declines as the thymus involutes.
Limitations: Gene therapy approaches for thymulin restoration are at the animal study stage only. No human gene therapy trials for thymulin have been conducted.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not in clinical development. No therapeutic product exists for thymulin.
Availability: Not available as a therapeutic product. Research-grade material available for laboratory use only.
Class context: Thymulin is a naturally occurring (the body's own) thymic hormone. Exogenous administration in research settings shows favorable tolerability. Zinc status directly affects biological activity.
Thymulin is a naturally occurring (the body's own) thymic hormone. No safety concerns have been identified from normal physiological activity. Exogenous administration is investigational with limited human safety data.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Thymulin (FTS/ZnFTS) discussion.
Comparison and Related Research
Thymulin is one of several thymic factors studied for immune function. The comparisons below clarify how it relates to other thymic peptides.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.The foundational study that isolated and purified the circulating thymic factor (later renamed thymulin) from porcine serum. This work established the biochemical identity of a serum factor produced by thymic epithelial cells, setting the stage for decades of research into thymic peptide immunology.Dardenne M et al., 1977 in J Biol Chem. View on PubMed
- 2.A detailed examination of the zinc-dependent activity of thymulin, demonstrating that the peptide requires a zinc ion to adopt its biologically active conformation. The paper explored how zinc deficiency impairs thymulin function and, by extension, thymus-dependent immune regulation.Dardenne M, 1994 in Met Based Drugs. View on PubMed
- 3.A comprehensive review of how the zinc-thymulin axis changes across the lifespan. The authors documented declining thymulin activity with age and linked this decline to zinc bioavailability, proposing that zinc supplementation could partially restore thymic endocrine function in older adults.Mocchegiani E et al., 2006 in Ageing Res Rev. View on PubMed
- 4.An early review connecting neuroendocrine regulation to thymic function. Fabris outlined how hormonal changes during aging contribute to thymic involution and diminished thymulin output, and proposed that interventions targeting the neuroendocrine-thymus axis could modulate immune senescence.Fabris N, 1988 in Ann N Y Acad Sci. View on PubMed
- 5.A human study measuring serum thymulin levels in individuals with experimentally induced mild zinc deficiency. Thymulin activity decreased during the zinc-deficient period and recovered after zinc repletion, providing direct evidence in humans that zinc status governs thymulin bioactivity.Prasad AS et al., 1988 in J Clin Invest. View on PubMed
- 6.A wide-ranging review of thymulin physiology covering its zinc dependence, neuroendocrine interactions, and emerging therapeutic applications. The authors summarized preclinical evidence for thymulin's anti-inflammatory and analgesic properties beyond classical immune regulation.Reggiani PC et al., 2009 in Ann N Y Acad Sci. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.